An overview on cystic fibrosis: Comprehensive insight and current developments

Saswati Tarafdar Sasmal
BCDA College of Pharmacy & Technology, Hridaypur, Kolkata – 700 127, West Bengal
Email: saswatits.pharmacy@gmail.com

1. Introduction

Cystic fibrosis (CF) is a genetic disorder that significantly impacts the respiratory and digestive systems affecting approximately 70,000 people globally. It's well known that orphan diseases are conditions that affect a small percentage of the population, often lacking sufficient treatment options. Likely, CF is also classified as an orphan disease in many countries due to its rarity (1-3). This article aims to provide a comprehensive understanding of cystic fibrosis, its impact as a rare disease, its genetic basis, symptoms, diagnosis, treatment options, and the latest research developments.

2. Understanding cystic fibrosis

Cystic fibrosis is an inherited disorder resulting from mutations in the CFTR (cystic fibrosis transmembrane conductance regulator) gene. This gene is responsible for encoding a protein that controls the flow of salt and water into and out of cells. When this gene is mutated, it leads to the production of thick and sticky mucus, which can cause severe damage to the respiratory and digestive systems (1-4).

3. Genetic basis and inheritance

Genetic mechanism

CF is an autosomal recessive disorder, meaning a child must inherit two defective copies of the CFTR gene, one from each parent, to develop the disease. Individuals with only one defective gene are carriers and typically do not show symptoms but can pass the gene to their children (4,5).

Table 1. Genetic Inheritance of Cystic Fibrosis *(Source: Cystic Fibrosis Foundation)*

Parents' Genetic Status	Probability of Child with CF	Probability of Carrier Child	Probability of Non-Carrier Child
Both parents carriers	25%	50%	25%
One parent carrier	0%	50%	50%
Neither parent carrier	0%	0%	100%



Figure 1. How CF Affects the Body (Source: Cystic Fibrosis Foundation)

4. Symptoms and diagnosis

4.1 Symptoms

The symptoms of cystic fibrosis can vary widely among individuals, but they generally include:

- **Respiratory issues:** Chronic coughing, wheezing, and frequent lung infections such as pneumonia or bronchitis.
- **Digestive problems:** Poor growth, weight gain despite a good appetite, frequent greasy and bulky stools, and intestinal blockages.
- **Salty-tasting skin:** High salt levels in sweat.
- **Infertility in males:** Due to blockage or absence of the vas deferens.

4.2. Diagnostic Methods

CF is typically diagnosed through a combination of tests:

- **Newborn Screening**: Conducted at birth to identify CF early.
- **Sweat Test**: Measures the concentration of salt in sweat, which is elevated in CF.
- **Genetic Testing**: Identifies mutations in the CFTR gene.



Figure 2. Diagnostic Pathway for Cystic Fibrosis (Source: Cystic Fibrosis Foundation)

5. Medication for cystic fibrosis

Treatment for CF typically involves a combination of therapies aimed at managing symptoms, preventing complications, and addressing the underlying genetic cause. The following categories of medications are commonly used (6-14).

5.1 CFTR modulators

CFTR modulators are a recent advancement in CF treatment. These drugs target the defective CFTR protein, improving its function. Types of CFTR modulators include:

- **Ivacaftor (Kalydeco):** Works by improving the function of the CFTR protein at the cell surface. It is effective for people with specific CFTR mutations (e.g., G551D).
- **Lumacaftor/Ivacaftor (Orkambi):** Combination therapy for individuals with two copies of the F508del mutation. Lumacaftor helps the CFTR protein reach the cell surface, and Ivacaftor enhances its function.
- **Tezacaftor/Ivacaftor (Symdeko):** Similar to Orkambi, it helps the CFTR protein to reach the cell surface and function properly, suitable for certain mutations including F508del.
- **Elexacaftor/Tezacaftor/Ivacaftor (Trikafta):** A triple combination therapy for individuals with at least one F508del mutation, it significantly improves lung function and quality of life.

5.2 Antibiotics

Used to treat and prevent lung infections. They can be administered orally, inhaled, or intravenously depending on the severity of the infection.

- **Tobramycin** (inhaled): Commonly used to treat chronic *Pseudomonas aeruginosa* infections.
- **Azithromycin:** An oral antibiotic that also has anti-inflammatory properties.

5.3 Mucus thinners

These medications help to thin and loosen the thick mucus in the lungs, making it easier to clear.

- **Dornasealfa (Pulmozyme):** An inhaled medication that breaks down DNA in the mucus, reducing its viscosity.
- **Hypertonic saline:** An Inhaled saline solution that helps draw water into the airways to thin the mucus.

5.4 Anti-inflammatory medications

Reduce inflammation in the lungs to prevent damage.

- **Ibuprofen:** High-dose ibuprofen can slow the decline of lung function in some children with CF.
- **Corticosteroids:** Used less frequently due to side effects, but can be beneficial in certain situations

.

5.5 Bronchodilators

Help open the airways by relaxing the muscles around them, making it easier to breathe.

- **Albuterol:** Often used before airway clearance therapies to open the airways.

5.6. Digestive enzymes

Since CF can block the pancreas, leading to malabsorption, pancreatic enzyme replacement therapy is crucial.

- **Pancrelipase (Creon, Pancreaze):** Helps digest food and absorb nutrients.

5.7. Vitamins and supplements

People with CF often require fat-soluble vitamins (A, D, E, and K) due to malabsorption.

5.8 Other therapies

- **Airway clearance techniques (ACTs)**: Chest physiotherapy and mechanical devices that help to clear mucus from the lungs.
- **Nutritional support**: High-calorie nutritional plans and vitamins.
- **Lung transplantation:** In extreme conditions, individuals with cystic fibrosis may undergo lung transplantation as a treatment option.

6. Management of cystic fibrosis

Management of CF is comprehensive and typically involves a multidisciplinary approach. Regular monitoring and proactive treatment adjustments are essential to address the changing needs of individuals with CF. Research is ongoing to find better treatments and ultimately a cure for this condition.



Figure 3. Impact of CFTR Modulators (Source: Cystic Fibrosis Foundation)

Table 2. Common CF Treatments (Source: Cystic Fibrosis Foundation)

Treatment Type	Description	Purpose
Airway Clearance Techniques	Methods to loosen and remove mucus	Improve breathing and reduce infection
Inhaled Medications	Bronchodilators, antibiotics, hypertonic saline	Open airways, fight infection, thin mucus
Pancreatic Enzymes	Supplements to aid digestion	Improve nutrient absorption
CFTR Modulators	Drugs targeting the defective CFTR protein	Improve lung function and overall health

7. Living with cystic fibrosis

7.1 Daily management

Managing CF involves a rigorous daily regimen, including airway clearance, medication adherence, and regular check-ups. Nutritional support is essential due to challenges with nutrient absorption, necessitating a high-calorie, high-fat diet (2).

7.2 Psychological and social support

The chronic nature of CF can affect mental health. Access to psychological support, counselling, and CF-specific support groups is vital. These resources help patients and their families cope with the emotional and social challenges posed by the disease.

8. Prognosis

The prognosis for individuals with CF has improved significantly over the past few decades due to advances in treatment. The average life expectancy has increased, with many individuals living into their 30s, 40s, and beyond. Continuous medical advancements and comprehensive care are key factors in enhancing both lifespan and quality of life for those with cystic fibrosis (2,3).

9. Research and future directions

9.1 Ongoing research

Research is focused on finding better treatments and a potential cure for CF. Key areas include:

- **Gene Therapy**: Strategies to correct the defective CFTR gene.
- **Stem Cell Therapy**: Potential to regenerate damaged tissues.
  Advanced CFTR Modulators: Developing drugs that target a broader range of CFTR mutations.

9.2. Promising developments

Recent advances in gene editing technologies, such as Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), show promise for directly correcting CFTR mutations. Ongoing clinical trials are exploring these innovative treatments' safety and efficacy.



Figure 4. Gene Therapy Process (Source: National Human Genome Research Institute)

Conclusion

Cystic fibrosis is a challenging condition, but advancements in treatment and research provide hope for better management and, eventually, a cure. Continued support and awareness are essential to improving the lives of those affected by CF. For the latest information on CF and its treatments; it's always advisable to consult resources like the Cystic Fibrosis Foundation or a healthcare provider specializing in CF care.

References

1. Shteinberg M, Haq IJ, Polineni D, Davies JC. Cystic fibrosis. Lancet. 2021;397(10290):2195-2211
2. About cystic fibrosis. Cystic Fibrosis Foundation. Accessed May 14, 2024.
3. Cystic fibrosis. National Organization for Rare Disorders. Accessed May 15, 2024.
4. Ratjen F, Döring G. Cystic fibrosis. Lancet. 2003;361(9358):681-9.
5. Cutting GR. Cystic fibrosis genetics: from molecular understanding to clinical application. Nat Rev Genet. 2015;16(1):45-56.
6. Davies JC, Moskowitz SM, Brown C, et al; VX16-659-101 Study Group. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med. 2018 Oct 25;379(17):1599-1611.
7. Keating D, Marigowda G, Burr L, et al; VX16-445-001 Study Group. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med. 2018 Oct 25;379(17):1612-1620.
8. Flume PA, Mogayzel PJ Jr, Robinson KA, et al; Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009 Nov 1;180(9):802-8.
9. Elkins MR, Robinson M, Rose BR, et al; National Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006 Jan 19;354(3):229-40.
10. Fuchs HJ, Borowitz DS, Christiansen DH, et al; The Pulmozyme Study Group. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med. 1994 Sep 8;331(10):637-42.
11. Konstan MW, Davis PB. Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis. Adv Drug Deliv Rev. 2002 Dec 23;54(11):1409-23.
12. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med. 1995 Mar 30;332(13):848-54.
13. Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2002 Sep;35(3):246-59.
14. Salles C, Ruffin M, Leroux JC. The challenges in the development of pancreatic enzyme replacement therapies for cystic fibrosis. Adv Drug Deliv Rev. 2017 Mar;112:104-16.